Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Novel Directions in Adjuvant Chemotherapy for Early Stage Epithelial Ovarian Cancer

  • Sakarya, Derya Kilic (Department of Obstetrics and Gynecology, Konya Training and Research Hospital) ;
  • Yetimalar, M Hakan (Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Ozbasar, Demir (Department of Obstetrics and Gynecology-emeritus, Suleyman Demirel University Faculty of Medicine)
  • Published : 2015.06.03
Download PDF
⟨ Previous Next ⟩

Abstract

Treatment of early stage ovarian cancer remains controversial despite advances in chemotherapeutic options. Over the past 30 years, molecular and clinicopathologic studies accelerated and treatment of ovarian cancer has undoubtedly improved although there is a debate as to whether this impacts outcome or not. More recently, the introduction of targeted therapy started a new era. Probably it is because early stage disease comprises a small portion of the epithelial ovarian cancer, studies have mostly ignored this group and still there is no clear consensus regarding systemic treatment of early-stage lesions. However this group of patients has the best chance of cure. In this review, we focus on current developments in the treatment of early stage ovarian cancer and query the options.

Keywords

References

  1. Adams G, Zekri J, Wong H, Walking J, Green JA (2010). Platinumbased adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG, 117, 1459-67. https://doi.org/10.1111/j.1471-0528.2010.02635.x
  2. Arikan SK, Kasap B, Yetimalar H et al (2014). Impact of prognostic factors on survival rates in patients with ovarian carcinoma. Asian Pac J Cancer Prev, 15, 6087-94. https://doi.org/10.7314/APJCP.2014.15.15.6087
  3. Bell J, Brady MF, Young RC et al (2006). Randomized phase III trial of three versus six cycles. Gynecol Oncol, 102, 432-9. https://doi.org/10.1016/j.ygyno.2006.06.013
  4. Chan JK, Tian C, Teoh D et al, (2010). Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 116, 307-11. https://doi.org/10.1016/j.ygyno.2009.10.074
  5. Chan JK, Tian C, Fleming GF, et al (2010). The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a gynecologic oncology group study. Gynecol Oncol, 116, 301. https://doi.org/10.1016/j.ygyno.2009.10.073
  6. Colombo N, Guthrie D, Chiari S et al (2003). International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst, 95, 125-32. https://doi.org/10.1093/jnci/95.2.125
  7. Collinson F, Qian W, Fossati R, et al; ICON1 collaborators, (2014). Optimal treatment of early-stage ovarian cancer. Ann Oncol, 25, 1165-71. https://doi.org/10.1093/annonc/mdu116
  8. Dizon DS, Restivo A, Lomme M, et al (2008). For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Am J Clin Oncol, 31, 39. https://doi.org/10.1097/COC.0b013e318134ee6f
  9. Fotopoulou C, Braicu I, Sehouli J (2012). Fertility-sparing surgery in early epithelial ovarian cancer: a viable option? Obstet Gynecol Int, 2012, 238061.
  10. Guvenal T, Dursun P, Hasdemir P, et al (2013). Effect of surgical staging on 539 patients with borderline ovarian tumors: a turkish gynecologic oncology group study. Gynecologic Oncology, 131, 546-50. https://doi.org/10.1016/j.ygyno.2013.08.038
  11. Jansaka N, Suprasert P (2014). Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center. Asian Pac J Cancer Prev, 15, 10837-40.
  12. Kajiyama H, Shibata K, Mizuno M, et al (2011). Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecol Oncol, 122, 334-8. https://doi.org/10.1016/j.ygyno.2011.04.016
  13. Kajiyama H, Shibata K, Mizuno M, et al (2011). Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible? Hum Reprod, 26, 3297-02. https://doi.org/10.1093/humrep/der342
  14. Kajiyama H (2014). Fertility sparing surgery in patients with early stage epithelial ovarian cancer: implication of survival analysis and lymphadenectomy. J Gynecol Oncol, 25, 270-1. https://doi.org/10.3802/jgo.2014.25.4.270
  15. Karimi Zarchi M, Mousavi A, Gilani MM, et al (2011). Fertility sparing treatments in young patients with gynecological cancers: Iranian experience and literature review. Asian Pac J Cancer Prev, 12, 1887-92.
  16. Kleppe M, Wang T, Van Gorp T, et al (2011). Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol, 123, 610-4. https://doi.org/10.1016/j.ygyno.2011.09.013
  17. Kolomainen DF, A'Hern R, Coxon FY, et al (2003). Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol, 21, 3113-8. https://doi.org/10.1200/JCO.2003.06.119
  18. Lazarov N, Lazarov L, Lazarov S (2013). The role of adjuvant chemotherapy as a prognostic factor in patients with early stage of epithelian ovarian cancer (I - II stage). Akush Ginekol (Sofiia), 52, 58-61.
  19. Malpica A, Deavers MT, Lu K, et al (2004). Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol, 28, 496-504. https://doi.org/10.1097/00000478-200404000-00009
  20. Maltaris T, Seufert R, Fischl F (2007). The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol, 130, 148-55. https://doi.org/10.1016/j.ejogrb.2006.08.006
  21. Mannel RS, Brady MF, Kohn EC, et al (2011). A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol, 122, 89-94. https://doi.org/10.1016/j.ygyno.2011.03.013
  22. National Comprehensive Cancer Network (NCCN), (2014). http://www.nccn.org/.
  23. NCT01462890. http://www.ago-ovar.de/en/trials-closedtrials-15.html.
  24. Patrono MG, Minig L, Diaz-Padilla I, et al (2013). Borderline tumours of the ovary, current controversies regarding their. Ecancermedicalscience, 7, 379.
  25. Perren TJ, Swart AM, Pfisterer J et al; ICON7 Investigators (2011). A phase 3 trial of bevacizumab in ovarian cancer, 365, 2484-96. https://doi.org/10.1056/NEJMoa1103799
  26. Raja FA, Chopra N, Ledermann JA (2012). Optimal first-line treatment in ovarian cancer. Ann Oncol, 23, 118-127. https://doi.org/10.1093/annonc/mds315
  27. Satoh T, Hatae M, Watanabe Y, et al (2010). Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol, 28, 1727-32. https://doi.org/10.1200/JCO.2009.24.8617
  28. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  29. Takada T, Iwase H, Iitsuka C, et al (2012). Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients. Int J Gynecol Cancer, 22, 573-8. https://doi.org/10.1097/IGC.0b013e31823fd413
  30. Trimbos JB, Vergote I, Bolis G et al (2003). Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: european organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl, 95, 113-25.
  31. Trimbos B, Timmers P, Pecorelli S et al (2010). Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst, 102, 982-7. https://doi.org/10.1093/jnci/djq149
  32. Tognon G, Carnazza M, Ragnoli M et al (2013). Prognostic factors in early-stage ovarian cancer. Ecancermedicalscience, 7, 325.
  33. Winter-Roach BA, Kitchener HC, Lawrie TA (2012). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev, 3, CD004706.
  34. Young RC, Brady MF, Nieberg RK, et al (2003). Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol, 21, 4350. https://doi.org/10.1200/JCO.2003.02.154

Cited by

  1. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6973